On the 30th of July, 2004, Russian Ministry of Health - the equivalent of the Food and Drug Administration in the United States - approved two 4Life products: Transfer Factor Classic and Transfer Factor Plus for use in hospitals and clinics in the Russian Federation.

It was an unprecedented announcement in the history of network marketing. No other company has never been recognized by the official medical establishment in this way. 4Life products became first ever dietary supplements to be approved for use by doctors and hospitals in Russia.

The recognition was based on the results of ten separate clinical trials and two experimental studies on 4Life Transfer Factor products, i. a.:

• Rak, AV et al. Effectiveness of Transfer Factor (TF) in the Treatment of Osteomyelitis Patients. International Symposium in Moscow 2002, Nov 5-7, 62-63.
• Granitov, VM et al. Usage of Transfer Factor Plus in Treatment of HIV - Infected Patients. Russian Journal of HIV, AIDS and Related Problems 2002, 1, 79-80.
• Karbysheva, NV et al. Enhanced Transfer Factor in the Complex Treatment of patients with Opisthorchiasis. International Symposium in Moscow 2002, May, 104-105.
• Luikova, SG et al. Transfer Factor in Dermatovenerology. Syberian Journal of Dermatology and Venerology 2002, 3, 34-35.

The up-to-date list of most of the world scientific research done on Transfer Factor can be obtained from:
http://www.transferfactorinstitute.com/Research/references.cfm

The researches conducted in Russia were combined in 32-pages of Methodological Document that was approved by the Ministry of Health. This way the Ministry allowed doctors to recommend 4Life Transfer Factor Classic and 4Life Transfer Factor Plus products to their patients and use the products in official clinical treatments.

There were some scientific experiments conducted there showed that NK cells activated with 4Life Transfer Factor Plus Advanced Formula killed 97 percent of cancerous cells, which exceeded the Interleukin-2 (IL2) activation kill rate of 88% during the same time period. The Russian scientists who conducted this study found the results to be exceptional and requested further information so their results could be published in professional journals. Dr. Kisielevsky, Russian Academy of Medical Sciences amazed with the results stated: “The 4Life sample (4Life Transfer Factor Plus Advanced Formula) activated NK cell activity more than the Interleukin-2 (IL-2) drug used as the standard. Here, we now refer to your sample as the Golden Interleukin”.

Russia is considered to have the second technologically advanced medical industry in the world. Therefore, interest of Russian scientific institutions into 4Life products and the recognition the products gained are prestigious for the company. Yet, for patients, awareness of that fact gives the true sense of security as the products might be used under the physician's care, not behind his back.